U.S. Jury Orders Takeda To Pay $6 Billion In Damages In Actos Case
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical was ordered by a U.S. court jury to pay $6 billion in punitive damages, its partner Eli Lilly $3 billion, to settle a case brought by a user of the Japan firm's Actos (pioglitazone) diabetes drug since pulled from the market.